Stem cells
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
Search
Search results
Look Forward – Winter 2022 – Issue 178
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
Applying for research funding
We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.
Research news round-up – Spring 2024
A round-up of the latest research into inherited retinal conditions - February 2024.
Look Forward – Summer 2023 – Issue 180
Did you join either of our Conferences this year? You can read about them inside this edition of Look Forward. We’ve had some fantastic feedback from our delegates so if you weren’t able to attend, you can watch or listen to the recordings from the day on our website.
Look Forward – Summer 2022 – Issue 177
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.
Research news roundup – innovation in 2022
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
ReNeuron trial FAQs
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.